osteomiR™ testing kit


osteomiR™ testing kit


Tamirna Logo

Products & Services | TAmiRNA GmbH

Overview:

The osteomiR™ research testing kit marks a world first: a diagnostic kit for musculoskeletal diseases and osteoporosis based on the detection of circulating microRNAs, obtained from a simple blood specimen sample.

The osteomiR™ kit thus provides a novel tool to analyze novel biomarker candidates for the prediction of fracture risk in postmenopausal women and can solve the problem of identifying patients in need of preventive therapy for bone fractures.

Background

Osteoporosis is a major medical problem, accounting for some 3.5 million bone fractures in Europe and more than 8.9 million fractures worldwide, resulting in an osteoporotic fracture every 3 seconds. with associated annual costs due to osteoporotic fractures estimated at €40 bn and this only in Europe.

For elder patients in particular, osteoporosis causes pain and instability, degrading quality of life and resulting in higher mortality.

The osteomiR™ kit’s development originated from an academic research project conducted at the laboratory of Prof. Johannes Grillari at the Department of Biotechnology, University of Natural Resources and Life Sciences, Vienna.

The research produced the first blood-based biomarker signature for fracture risk in postmenopausal osteoporosis.

Features

The osteomiR™ kit is initially intended or research-use only, to include clinical research and secondary outcome of clinical trials. It is particularly useful for pharmaceutical companies and clinical research groups active in osteoporosis and age-related diseases.

It is based on a combination of several microRNAs (“signature”) biomarkers that can assess fracture-risk due to osteoporosis in post-menopausal women. This is analysis is simplified through the implementation of a software solution with a user-friendly interface.

The test is designed to provide a valuable complement to clinical parameters such as FRAXTM or bone mineral density, improving its test performances significantly.

Benefits

The osteomiR™ kit’s main end-user benefits include:

  • A standardized workflow for circulating microRNA analysis
  • Sophisticated panel of controls to generate high quality data
  • Rapid test results
  • High sensitivity and specificity
  • Minimal invasiveness

The kit enables simple and rapid analysis of osteomiRs, microRNAs with strong association to fracture-risk in different forms of osteoporosis. These biomarkers will enable personalized risk assessment of bone fractures due to osteoporosis at an early stage. Consequently, preventive treatment can start much earlier and can be targeted to patients in need of therapy. Targeting treatments to those patients in need helps to prohibit bone fractures, pain and suffering, avoid overtreatment and reduce the socioeconomic burden of osteoporosis.

The osteomiR™ miRNA kit enables a minimal invasive test requiring only a blood sample. It is based on a simple technology platform, making to easy to handle for practitioner or medical specialist.

The miRNA testing model provides improved sensitivity and specificity for early detection of osteoporosis and the high risk of bone fractures, improving the utility of gold-standard bone densitometry.

Further information and availability

TAmiRNA osteomiR™ test kit is available to order from our web page: http://www.tamirna.com/osteomir/

There is also background and support information on the new TAmiRNA osteomiR™ test kit on our home page: https://www.tamirna.com

Media Contacts

Birgit Marckhgott, TAmiRNA, GmbH
Tel: +43 (0)660 420 58 56
Email: office@tamirna.com

Resources

Click on osteomiR™ testing kit for other information.
Click on TAmiRNA to contact the company directly.
Click on osteomiR specifications for product information.


Supplier Information
Supplier: TAmiRNA GmbH
Address: Muthgasse 18, 1190 Vienna, Austria
Tel: +43 (0)660 420 58 56
Website: www.tamirna.com/


Comments are closed.